Immunohistochemistry on cytology specimens from pleural and peritoneal fluid



Similar documents
Diagnostic Challenge. Department of Pathology,

Cytology : first alert of mesothelioma? Professor B. Weynand, UCL Yvoir, Belgium

How To Diagnose And Treat A Tumour In An Effusion

Cytopathology Case Presentation #8

Practical Effusion Cytology

MALIGNANT MESOTHELIOMA UPDATE ON PATHOLOGY AND IMMUNOHISTOCHEMISTRY

Update on Mesothelioma

MALIGNANT MESOTHELIOMA UPDATE ON PATHOLOGY AND IMMUNOHISTOCHEMISTRY

How To Test For Cancer

Cytology of Effusion Fluids. Cytology of Effusion Fluids. Types of Effusion Fluids. Anatomy. Causes of Effusions. Sampling of Effusion Fluids

Diagnosis of Mesothelioma Pitfalls and Practical Information

The develpemental origin of mesothelium

Disclosures. Learning Objectives. Effusion = Confusion. Diagnosis Of Serous Cavity Effusions - Beware The Mesothelial Cell!

Effusions: Mesothelioma and Metastatic Cancers

PATHOLOGY OF THE PLEURA: Mesothelioma and mimickers Necessity of Immunohistochemistry. M. Praet

Ovarian tumors Ancillary methods

Immunohistochemical differentiation of metastatic tumours

HKCPath Anatomical Pathology Peer Review and Scores : PDF version for download

Outline. Workup for metastatic breast cancer. Metastatic breast cancer

Académie internationale de Pathologie - Division arabe XX ème congrès novembre 2008 Alger. Immunohistochemistry in malignant mesotheliomas

Video Microscopy Tutorial 5

Diseases. Inflammations Non-inflammatory pleural effusions Pneumothorax Tumours

Seattle. Case Presentations. Case year old female with a history of breast cancer 12 years ago. Now presents with a pleural effusion.

Notice of Faculty Disclosure

3-F. Pathology of Mesothelioma

ThinPrep Non-Gyn Lecture Series. Body Fluid Cytology

TUMORS OF THE TESTICULAR ADNEXA and SPERMATIC CORD

Case of the. Month October, 2012

INFLAMMATORY PLEURAL EFFUSION

PRIMARY SEROUS CARCINOMA OF PERITONEUM: A CASE REPORT

A. Pericardial smear. Examination of the pericardial aspirate can provide useful diagnostic information.

Today s Topics. Tumors of the Peritoneum in Women

A 70-year old Man with Pleural Effusion

Carcinosarcoma of the Ovary

Effusion cytology. Dr Alpha Tsui Royal Melbourne Hospital 2008

The Use of Immunohistochemistry to Distinguish Reactive Mesothelial Cells From Malignant Mesothelioma in Cytologic Effusions

ORIGINAL ARTICLES. Materials and Methods

The diagnostic usefulness of tumour markers CEA and CA-125 in pleural effusion

20 Diagnostic Cytopathology, Vol 36, No 1 ' 2007 WILEY-LISS, INC.

Case presentation. Awatif Al-Nafussi

MALIGNANT MESOTHELIOMA: A TYPICAL PRESENTATION IN AN ATYPICAL PATIENT

Malignant Mesothelioma in Body Fluids - with Special Reference to Differential Diagnosis from Metastatic Adenocarcinoma -

Immunohistochemistry of soft tissue tumors

YOUR LUNG CANCER PATHOLOGY REPORT

Case based applications part III

The Value of Thyroid Transcription Factor-1 in Cytologic Preparations as a Marker for Metastatic Adenocarcinoma of Lung Origin

DESMOPLASTIC SMALL ROUND CELL TUMOR: A RARE PATHOLOGY PUZZLE

The Diagnostic Value of Pleural Fluid Cytology in Benign and Malignant Pleural Effusions

Pleural Mesothelioma: An Institutional Experience of 66 Cases

ESSENTIALS OF FLUID CYTOLOGY

A Cytokeratin- and Calretinin-negative Staining Sarcomatoid Malignant Mesothelioma

BAP1 germline mutations A new Cutaneous Nevus Melanoma Syndrome. Thomas Wiesner

ALTHOUGH excellent accounts have been published in recent years of

Case presentation: Mesothelioma of the tunica vaginalis. Dr Ben Shepherd Pathology Queensland Princess Alexandra Hospital Brisbane

The Diagnosis of Cancer in the Pathology Laboratory

Male. Female. Death rates from lung cancer in USA

How To Diagnose And Treat A Pleural Effusion

Case Report A Cause of Bilateral Chylothorax: A Case of Mesothelioma without Pleural Involvement during Initial Diagnosis

Changes in Breast Cancer Reports After Second Opinion. Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain

Fine Needle Aspiration Cytologic Features of Well-Differentiated Papillary Mesothelioma in the Pleura

Renal Cell Carcinoma: Advances in Diagnosis B. Iványi, MD

Diseases of peritoneum Lect. Al Qassim University, Faculty of Medicine Phase II Year III, CMD 332 Pathology Department 31-32

Deciduoid Mesothelioma:

The evolving pathology of solitary fibrous tumours. Luciane Dreher Irion MREH / CMFT / NSOPS

General Rules SEER Summary Stage Objectives. What is Staging? 5/8/2014

LYMPHOMA. BACHIR ALOBEID, M.D. HEMATOPATHOLOGY DIVISION PATHOLOGY DEPARTMENT Columbia University/ College of Physicians & Surgeons

Pericardial disease. Usually secondary to systemic or other cardiac diseases. Pericardial fluid accumulations Pericarditis

Cytology of Lymph Nodes

Case Report Epithelioid malignant mesothelioma presenting with features of gastric tumor in a child

Histopathology of Major Salivary Gland Neoplasms

ASBESTOS EXPOSURE AND SARCOMATOID MALIGNANT PLEURAL MESOTHELIOMA Gorantla Sambasivarao 1, Namballa Usharani 2, Tupakula Suresh Babu 3

Pathology of lung cancer

Silent Time-Bomb, Mesothelioma

Anatomy Pleura Visceral Layer outer surface of lung Separates lobes of lung from each other Parietal Layer inner surface chest wall Pleural linings Co

Index. F Factor VIII-related antigen, see VWF FactorXIIIa, for dermatofibroma, HT, see Serotonin

Role of immunohistochemistry

Pathology of the Female Peritoneum, Common and Uncommon Problems

SEROUS EFFUSION CYTOLOGY- A PRACTICAL APPROACH

MESOTHELIAL DIFFERENTIATION, MESOTHELIOMA AND TUMOR MARKERS IN SEROUS CAVITIES

Protocol applies to all primary borderline and malignant epithelial tumors, and malignant mesothelial neoplasms of the peritoneum.

Carbohydrate antigen 19 9 (CA 19 9) (serum, plasma)

Protocol for the Examination of Specimens From Patients With Tumors of the Peritoneum

Neoplasms of the LUNG and PLEURA

PROTOCOL OF THE RITA DATA QUALITY STUDY

INFLAMMATION AND REACTIVE CHANGES IN CERVICAL EPITHELIUM

Thoracic Cavity. Photo: This normal canine lung collapsed when the thorax was opened and the negative pressure was lost in the thorax.

How To Test For Cancer With A Blood Test

Functions of Blood. Collects O 2 from lungs, nutrients from digestive tract, and waste products from tissues Helps maintain homeostasis

Lymphohistiocytoid Mesothelioma An Often Misdiagnosed Variant of Sarcomatoid Malignant Mesothelioma

Basic Professional Training Program for Associate Medical Technologist

METASTATIC CLEAR CELL RENAL CELL CARCINOMA TO THE SUBCUTANEOUS AREA IN ILLIAC FOSSA AND ADRENAL GLAND WITHOUT AN IDENTIFIABLE PRIMARY TUMOR

FNA Cytology of Mediastinal Lesions. Presenters: Xiaoqi Lin, M.D., Ph.D. Ritu Nayar, M.D.

Tumour Markers. What are Tumour Markers? How Are Tumour Markers Used?

Transcription:

Immunohistochemistry on cytology specimens from pleural and peritoneal fluid Dr Naveena Singh Consultant Pathologist Bart health NHS Trust London United Kingdom

Disclosures and Acknowledgements I have no financial disclosures. I would like to acknowledge the use of images from Diagnostic Cytopathology and Professor Mike Sheaff, my colleague and co-author.

Learning Objectives Problems with pathological assessment of serous effusion fluids Role of immunohistochemistry; antibodies/panels useful in routine practice Common sense approach for safe reporting

Introduction One of the most challenging areas in cytology reporting One of the areas most dependent on good quality immunohistochemistry: technical quality interpretation

Anatomy of the serous cavities

Structure and function of mesothelium Mesothelium: Single layer of epithelioid cells on a bed of vascular connective tissue Submesothelial cells - progenitors of surface epithelioid cells; possibly the cells of origin of malignant mesothelioma Stroma with network of capillaries and lymphatics

Structure and function of mesothelium Normal serous fluid production: Blood parietal stromal matrix mesothelial layer serous cavity Normal serous fluid resorption: into capillaries of visceral serosa through stomata between mesothelial cells into lymphatics within the parietal serosa Functions: Produce hyaluronate-rich fluid Facilitate transport of fluid and cells across serosal barrier Also: Phagocytic function antigen presentation, inflammatory processes, coagulation, fibrinolysis, repair and tumour cell adhesion

Structure and function of mesothelium Mesothelial lining cells Flat /cuboidal, Small to medium sized nuclei, small nucleoli Variable amounts of cytoplasm with luminal microvilli on the luminal Pinocytotic vesicles on both apical and basal sides of the cell

Histology of mesothelial cells - normal

Calretinin

D2-40 CD68

Effusions Transudate Exudate Protein low <2.9g/dl Non-fibrinous Protein high (>3g/dl) Fibrin present Cell content low LDH low Specific gravity low <1.015 Clear Inflammatory/tumour cells LDH high Specific gravity higher Microorganisms or foreign material

Transudate Exudate Common Left ventricular failure Liver cirrhosis Hypoalbuminaemia Peritoneal dialysis Common Malignancy Parapneumonic effusions Less common Hypothyroidism Nephrotic syndrome Mitral stenosis Pulmonary embolism Less common Pulmonary infarction Rheumatoid arthritis Autoimmune diseases Benign asbestos effusion Pancreatitis Post-myocardial infarction syndrome

Histology of mesothelial cells - reactive

Calretinin D2-40 CD68

Cytology of mesothelial cells round with indistinct cell membranes and fuzzy borders single or clumped with so-called windows between cells large round or elliptical nucleus, often centrally placed, with a single prominent nucleolus may contain two or multiple nuclei cytoplasm is green with Papanicolaou and blue with MGG 2-zone cytoplasm vacuoles due to degeneration or pinocytosis or glycogen

Other cells in effusion fluid Macrophages Lymphocytes: T>>B Neutrophils Eosinophils Plasma cells Mast cells Megakaryocytes

Challenges in effusion cytology in the presence of malignancy Multiple causes of effusions; may be due to a co-morbidity, not the cancer May be first manifestation of malignancy Even when due to cancer, this may be due to lymphatic blockage Irritation of mesothelium ie NOT tumour cell seeding Difficulties in interpretation

Challenges in effusion cytology Interpretation challenges Reactive mesothelial cells can show a range of atypia: bi-/multinucleation, nuclear atypia, mitotic activity, large cell aggregates, vacuolation, gland-like arrangement Malignant cells are altered in effusions Polygonal shape 3-D aggregates Degenerative changes Do not resemble the primary Look similar irrespective of origin Some types deceptively bland Number of cells present in the fluid is highly variable

Role of immunohistochemistry 1. MALIGNANT OR REACTIVE? Dual population but only subtle differences or overlapping features Single population of only malignant cells without obvious cytological features of malignancy Isolated malignant cells in a vast reactive population

Malignant vs Reactive Mesothelial Carcinoma Calretinin B72.3 D2-40 BerEP4 CK 5/6 Vimentin Use a panel including +ve and ve markers CARE when interpreting which cells are positive for what: SCIP CD15 CEAm EMA (cytoplasmic) MOC31

Malignant vs Reactive Mesothelial Carcinoma Calretinin B72.3 D2-40 BerEP4 CK 5/6 Vimentin Use a panel including +ve and ve markers CARE when interpreting which cells are positive for what: SCIP CD15 CEAm EMA (cytoplasmic) MOC31

MOC 31

Malignant vs Reactive Reactive mesothelial Mesothelioma Calretinin Calretinin D2-40 D2-40 CK 5/6 CK 5/6 Vimentin Vimentin EMA (negative/weak) EMA (membranous) Desmin (positive) Desmin (negative) Others: p53, bcl-2, Glut1

Calretinin

EMA: Strong membranous staining is typical in mesothelioma; Normal/reactive mesothelial cells: weak staining; Adenocarcinoma cells: diffuse strong cytoplasmic staining without membranous accentuation

Desmin: NEGATIVE in mesothelioma; positive in normal/reactive mesothelial cells

Role of immunohistochemistry 2. Determining primary site General markers of malignancy and negative markers of mesothelial cells and macrophages Specific markers for particular malignancies

Antibodies useful for determining site of origin in effusions Cancer Lung Ovary Gastrointestinal tract Breast Melanoma Lymphoma Sarcoma Antibodies TTF-1, CD56, CK19 WT-1 (also positive in mesothelial cells), ER CDX2, CK7/20, CA19-9, CEAm ER, mammoglobin, CRx-A01, S-100, HMB-45, melan A CD3:CD20, other specific studies Vimentin, other specific

Common Examples

Adenocarcinoma of lung: TTF1 +ve

TTF 1 CD56 Small cell carcinoma of lung: TTF1 and CD56 +ve

Gastric signet ring carcinoma: CEA positive CEA BerEp4 MOC31

ER +ve WT1 +ve Calret -ve High grade serous tubo-ovarian carcinoma

CD3 CD20

Pitfalls in interpreting IHC in effusions MIXTURE of cells: take care to report expression in the correct population; particularly in presence of low cellularity

WT1 expressed in mesothelial cells TTF1 expressed in malignant cells

Pitfalls in interpreting IHC in effusions PATTERN of expression where appropriate

Reactive mesothelial cells: weak diffuse cytoplasmic Mesothelioma: Cytoplasmic with STRONG membrane accentuation Adenocarcinoma: Diffuse strong cytoplasmic expression, obscures cellular detail EMA expression patterns

Question 1 Which of the following markers would not be useful in distinguishing reactive mesothelial cells from metastatic adenocarcinoma? 1. MOC31 2. BerEp4 3. Calretinin 4. CK7 5. CK 5/6

Question 2 Which of the following markers would not be useful in the diagnosis of mesothelioma? 1. MOC31 2. Actin 3. Calretinin 4. Desmin 5. EMA

Case 1: Pleural fluid in known case of lung cancer: reactive or metastatic?

Case 2: 19F, Fitz-Hugh-Curtis Syndrome. Rule out malignancy

General approach to reporting malignancy in effusions Only report when CERTAIN: malignancy is easy to overcall and undercall: err on side of caution Always rule out malignancy if there is a +ve history Always rule out malignancy if there is doubt on morphology Look at all preparations before issuing final report Use a PANEL of markers, not just one Take care when interpreting IHC as there is a mixture of cells present; coordinate approach on serial sections Due regard to expression by different cell types, eg WT1 Due regard to different patterns of expression, eg EMA Asking for another sample is not unreasonable